RISPERDAL(R) CONSTA(R) (Risperidone) Long-Acting Treatment Delayed the Time to Relapse in Patients with Bipolar I Disorder
... similar medications. TD includes uncontrollable
movements of the face, tongue, and other parts of the body. ... potentially irreversible, involuntary, dyskinetic
movements that may develop in patients treated with ... developing TD and the likelihood that dyskinetic
movements will become irreversible are believed to increase ...
Video: FDA Approves INVEGA(R) SUSTENNA(TM) for the Acute and Maintenance Treatment of Schizophrenia
... Call your doctor right away if you start to develop twitching or jerking
movements that you cannot control in your face, tongue, or other parts of your body. ... (shaking), shuffling, uncontrolled involuntary movements, and abnormal
movements of the eyes.
This is not a complete list of all possible side ...
Nektar Announces Positive Results from Phase 2 Study of Oral NKTR-118 in Patients with Opioid-Induced Constipation (OIC)
... statistically significant, dose-dependent increase in spontaneous bowel
movements (SBMs) from baseline after the first week of NKTR-118 treatment with the ... once-daily at the 25 mg and 50 mg dose levels dramatically increased bowel
movements within the first week of treatment for patients with OIC," said Lynn R. ...
Gene Therapy Improves Vision in Patients with Congenital Retinal Disease
... Patients' Vision Improved from Detecting Hand
movements to Reading
Lines on Eye Chart
PHILADELPHIA, April 27 ... no treatment for LCA.
"Patients' vision improved from detecting hand
movements to reading
lines on an eye chart," Maguire added. In 2001, Bennett and ...
Beaumont Patients 1st to get Next Generation of Radiation Treatment
... the radiation field during treatment to
account for a patient's external
movements - and the natural repositioning
of internal organs - from day to day or ... implants as with other therapies.
Its robotic component tracks a patient's
movements on a real-time basis and
corrects the treatment accordingly." Dr. ...
Procter & Gamble Pharmaceuticals Launches Asacol(R) HD (mesalamine) Delayed-Release Tablets
... clinical studies of moderately active UC flares, Asacol HD at 4.8 g/day helped many patients reduce their UC symptoms, including number of bowel
movements and rectal bleeding, for some as early as three weeks. Asacol HD decreased the number of trips to the bathroom (i.e., number of bowel movements) in ...
New Analysis Shows Efficacy of SIMPONI(TM) (golimumab) in Anti-TNF Experienced Rheumatoid Arthritis Patients
...
skin or eyes look yellow
little or no appetite
vomiting
muscle aches
dark urine
clay-colored bowel
movements
fevers
chills
stomach discomfort
skin rash
If you take SIMPONI(TM) or other TNF blockers, your ...
Two-Year Data Show Patients Receiving SIMPONI(TM) (golimumab) Experienced Sustained Improvement in Signs and Symptoms of Psoriatic Arthritis and Ankylosing Spondylitis
...
skin or eyes look yellow
little or no appetite
vomiting
muscle aches
dark urine
clay-colored bowel
movements
fevers
chills
stomach discomfort
skin rash
If you take SIMPONI(TM) or other TNF blockers, your ...
WORLD'S First Robotic Assisted Kidney Transplant Performed at Saint Barnabas Medical Center
... camera and robotic probes are inserted into the patient through several small incisions. Pencil-sized probes translate the surgeon's hand
movements and adjust themselves to compensate for the natural tremor of the human hand. For the patient, robot-assisted surgery is safe, minimally invasive ...
Study Demonstrating Lurasidone Is Effective in Patients With Schizophrenia Published in The Journal of Clinical Psychiatry
... lurasidone and placebo for EPS (assessed using the Simpson-Angus Scale) or symptoms of tardive dyskinesia (assessed using the Abnormal Involuntary
movements Scale). There was a modest but significant worsening at endpoint in akathisia symptoms (assessed using the Barnes Akathisia Scale) for lurasidone ...
Ironwood and Forest Present Additional Positive Phase 2b Study Results for Linaclotide in Patients With Irritable Bowel Syndrome With Constipation
... with CC often experience hard and lumpy stools, straining during defecation, a sensation of incomplete evacuation, and fewer than three bowel
movements per week. The discomfort and bloating of CC significantly affects patients' quality of life by impairing their ability to work and participate in ...
VA Studies Advanced Prosthetic Arm
... (DARPA), the study marks the first large-scale testing of the arm, which allows those who have lost a limb up to their shoulder joint to perform
movements while reaching over their head, a previously impossible maneuver for people with a prosthetic arm.
The study is under the direction of Dr. Linda ...
Optimer Pharmaceuticals Presents Results From Fidaxomicin Phase 3 Study for the Treatment of Clostridium difficile Infection
... 46% of the patients were over the age of 65, 56% were in-patients, 17% had a prior episode of CDI and study participants had an average of 8.3 bowel
movements per day.
The incidence of adverse events and serious adverse events between the fidaxomicin and Vancocin arms was similar.
Additional ...
Johnson & Johnson Pharmaceutical Research & Development, L.L.C. Announces FDA Filings for Paliperidone Palmitate and INVEGA(R)
... Tardive Dyskinesia (TD) is a serious, sometimes permanent side effect reported with paliperidone and similar medications. TD includes uncontrollable
movements of the face, tongue, and other parts of the body. The risk of developing TD and the chance that it will become permanent is thought to increase with ...
Michael J. Fox Foundation Awards $2.9 Million for Two New Parkinson's Disease Clinical Trials
... (marketed under the trade name Zocor), a drug currently used to treat high cholesterol, to reduce dyskinesias -- the disruptive, uncontrollable
movements that are a side effect of long-term dopamine replacement. The other team will undertake a Phase 2 study to determine whether isradipine (marketed ...
Schering-Plough Reports Preladenant Meets Primary Endpoint in Phase II Dose-Finding Trial for Parkinson's Disease
... II dose-finding trial in patients suffering from moderate to severe Parkinson's disease experiencing motor fluctuations and abnormal involuntary
movements (dyskinesias). The trial results were presented today at the company's 2008 R&D Update meeting being hosted for analysts and portfolio managers ...
Raptor Pharmaceuticals to Collaborate with Centre Hospitalier Universitaire d'Angers for Phase II Clinical Trial in Huntington's Disease
... to cause Huntington's, which results in the degeneration of
certain nerve cells in the brain. The disease is characterized by
uncontrollable
movements and mood swings or depression, followed by
dementia.
About Cysteamine and DR Cysteamine
Cysteamine is approved for sale by the FDA and European ...
Study Suggests Treatment with Paliperidone ER Significantly Improves Symptoms of Schizoaffective Disorder
... Tardive Dyskinesia (TD) is a serious, sometimes permanent side effect
reported with paliperidone and similar medications. TD includes
uncontrollable
movements of the face, tongue, and other parts of the body.
The risk of developing TD and the chance that it will become permanent is
thought to increase with ...
Ironwood and Forest Present Positive Phase 2b Study Results for Linaclotide in Patients With Irritable Bowel Syndrome With Constipation
... with CC often
experience hard and lumpy stools, straining during defecation, a sensation
of incomplete evacuation, and fewer than three bowel
movements per week.
The discomfort of CC significantly affects patients' quality of life by
impairing their ability to work and participate in typical ...
Ironwood and Collaborators Present Preclinical Data Demonstrating That Cyclic GMP Alleviates Intestinal Pain
... with CC often
experience hard and lumpy stools, straining during defecation, a sensation
of incomplete evacuation, and fewer than three bowel
movements per week.
The discomfort of CC significantly affects patients' quality of life by
impairing their ability to work and participate in typical ...
Ironwood Raises $50 Million to Advance Linaclotide Through Phase 3
... with CC often
experience hard and lumpy stools, straining during defecation, a sensation
of incomplete evacuation, and fewer than three bowel
movements per week.
The discomfort of CC significantly affects patients' quality of life by
impairing their ability to work and participate in typical ...
Ironwood and Forest to Present Positive Data From Linaclotide Phase 2b IBS-C Study at ACG Annual Scientific Conference
... with CC often
experience hard and lumpy stools, straining during defecation, a sensation
of incomplete evacuation, and fewer than three bowel
movements per week.
The discomfort of CC significantly affects patients' quality of life by
impairing their ability to work and participate in typical ...
Vision Problems Affect How Children Learn Math Skills
... field of deficits in vision
function, academic performance and eye movements. Unfortunately many
individuals do not know about the importance of eye
movements as an
integral part of vision and learning. Children with learning problems at
school can profit from these new methods of diagnosing and treating ...
Michael J. Fox Foundation Awards $2.7 Million for Industry Efforts to Speed New Parkinson's Therapeutics
... the gold-standard Parkinson's treatment,
levodopa, which could lessen debilitating side effects of the drug
including dyskinesias, the uncontrollable
movements that arise with
long-term levodopa therapy (Verne Cowles, Ph.D., and S. Y. Eddie Hou,
Ph.D., Depomed, Inc., Menlo Park, California);
-- Validating ...
New England Journal of Medicine Publishes Results From a RELISTOR Phase 3 Clinical Study
... to laxative
therapy has not been sufficient.
The clinical study showed that significantly more OIC patients with
advanced illness experienced bowel
movements (laxation) within four hours
of receiving their first dose of subcutaneous RELISTOR than patients
receiving placebo, without the use of a rescue ...
Wyeth and Progenics Announce Preliminary Clinical Trial Results for RELISTOR Oral and Intravenous Formulations
... the once daily oral formulation of RELISTOR showed
statistically significant activity as assessed by the occurrence of
spontaneous bowel
movements and other efficacy measures. This oral
formulation was also shown to be generally well tolerated.
"We are pleased by the preliminary findings of ...
Ironwood Pharmaceuticals and Forest Laboratories Announce Presentation of Linaclotide Phase 2b Chronic Constipation Study Results
... with CC often
experience hard and lumpy stools, straining during defecation, a sensation
of incomplete evacuation, and fewer than three bowel
movements per week.
The discomfort of CC significantly affects patients' quality of life by
impairing their ability to work and participate in typical ...
Patients Treated with Risperidone Long-Acting Injection had a Significantly Longer Time to Relapse Compared to Quetiapine in International Clinical Study
... Dyskinesia (TD) is a serious, sometimes permanent side effect
reported with risperidone, RLAI, and similar medications. TD includes
uncontrollable
movements of the face, tongue, and other parts of the body.
The risk of developing TD and the chance that it will become permanent is
thought to increase with ...
BARACLUDE(R) (Entecavir) Treatment Resulted In Greater Viral Load Suppression Compared to Adefovir at 96 Weeks In Antiviral-Naive Adult Chronic Hepatitis B E-Antigen Positive Patients
... signs of liver problems: yellowing (jaundice) of the skin
or the white part of the eyes, darkening of the urine, lightening in the
color of bowel
movements (stools), not feeling like eating food for several
days or longer, feeling sick to the stomach (nausea), or having lower
stomach pain. Lactic ...
Michael J. Fox Foundation Commits up to $10 Million for Pre-Clinical Drug Development Under Therapeutics Development Initiative
... beyond that offered by current therapies, including strategies to
alleviate complications of current treatments such as dyskinesias (the
disruptive
movements that are a side effect of long-term levodopa use).The
Foundation is also eager to support development of treatments that address
'non-motor' aspects ...
BARACLUDE(R) (entecavir) Data Continue to Demonstrate Low Incidence of Resistance Through Five Years of Treatment in Nucleoside-naive Chronic Hepatitis B Patients
... signs of liver problems: yellowing (jaundice) of the skin
or the white part of the eyes, darkening of the urine, lightening in the
color of bowel
movements (stools), not feeling like eating food for several
days or longer, feeling sick to the stomach (nausea), or having lower
stomach pain. Lactic ...
Microbia and Forest Laboratories Announce Preliminary Results of Linaclotide Phase 2b Studies
... with CC often
experience hard and lumpy stools, straining during defecation, a sensation
of incomplete evacuation, and fewer than three bowel
movements per week.
The discomfort of CC significantly affects patients' quality of life by
impairing their ability to work and participate in typical ...
Oxygen Relieves IBS and Constipation Symptoms in New Clinical Studies
... n/a 100% Improvement Relief for Passage of Mucous n/a 100% Improvement Reduction of Straining During Bowel
movements 85% Improvement 96% Improvement Success Rate (compared to Dulcolax) 85% More Effective 69% More ...
Seven-Year Neck Pain Study Sheds Light on Best Care
... before the stroke fully
develops.
"This type of stroke is extremely rare and has been known to occur
spontaneously or after ordinary neck
movements such as looking up at the
sky or shoulder-checking when backing up a car," noted the study's lead
author, Dr. David Cassidy, professor of ...
Nektar Commences Phase 2 Trial of NKTR-118 (oral PEG-naloxol) Evaluating Efficacy and Safety as Treatment for Opioid-Induced Bowel Dysfunction
... once-daily (QD) over
a five-week treatment period. The primary efficacy endpoint of the trial
will be the increase from baseline in spontaneous bowel
movements per week
(SBMs per week). Additional endpoints include monitoring of other symptoms
of OBD, which will include the Patient Assessment of Constipation ...
Five Clinical Studies to Receive $2.5 Million Under Foundation's 2007 Clinical Discovery Program
... the
patient's quality of life. Funded projects will address common and
debilitating aspects of PD such as depression, dyskinesia (the
uncontrollable
movements that are a side effect of long-term levodopa
treatment), sleep disorders and excessive salivation.
"The Michael J. Fox Foundation is committed to ...
Artists for a New South Africa Will be 'Shaking The Blues' at Gala Benefit November 15, With Performances by Erykah Badu, Nikka Costa, Keb' Mo', Taj Mahal Trio, The Roots, and Guest Stars at The Wiltern in Los Angeles
... equality, and assist and empower AIDS orphans and
other at-risk youth. By working in partnership with effective grassroots
organizations and pivotal
movements on the frontlines of these issues, ANSA
makes a substantial difference. Founded in 1989 to support South Africa's
quest to end apartheid and build a ...
Clinical Trial Results Suggest Long-Term Treatment Benefit of
Tetrabenazine for Chorea Associated with Huntington's Disease
... a brain chemical involved in abnormal
movements such as
chorea. Chorea can be a debilitating ... by excessive, involuntary and
repetitive
movements that may flow from one body part to another.
The
movements may involve the face, limbs or the entire body. ...
Blood Levels of Paliperidone Extended-Release Tablets are Not
Increased by Common Antidepressant
... TD is a syndrome of potentially
irreversible, involuntary, dyskinetic
movements that may develop in
patients treated with antipsychotic medications. The risk of
developing TD and the likelihood that dyskinetic
movements will
become irreversible are believed to increase with duration ...